FUNDAMENTOS DE FARMACOLOGIA - AULA 1

Main Ideas and Lessons

1. How to Prepare for the Course

Professor Jessica Bonato introduced the module schedule and noted that the first study activities were already available in the online learning environment.

Students were encouraged to review the textbook unit and conceptual lesson before attending live classes. The live sessions use an active-learning approach and are intended to build on—not simply repeat—the recorded material.

Students were asked to keep live-chat questions focused on the lesson and to use the “Talk to the Mediator” option for questions that could not be addressed during class.

2. Why Pharmacology Matters Across Health Professions

The lecturer presented pharmacology as a professional advantage for anyone involved in patient care. Understanding a patient’s medicines can help a professional recognize possible side effects, administration problems, or interactions that may affect treatment.

The central lesson was that pharmacology is relevant beyond prescribing: it can improve communication within care teams and the quality of patient support.

3. Drug Discovery, Development, and Evidence

The lecture used the discovery of penicillin to illustrate serendipity: Fleming noticed that mold growing on a contaminated culture plate appeared to inhibit nearby bacteria. The lecturer emphasized that scientific observation, persistence, and follow-up research turned that observation into a treatment.

The broader drug-development pathway was outlined as follows:

1. Basic research and discovery

   • Researchers investigate biological targets and potential compounds.
   • The lecture gave an approximate figure of 5,000–10,000 promising candidates at this early stage.

2. Preclinical testing

   • Candidates are assessed using methods such as computational modeling, cell and tissue studies, isolated-organ tests, and appropriate animal models.
   • Researchers investigate properties such as solubility, distribution, metabolism, toxicity, and possible activity.
   • The candidate pool narrows substantially; the lecturer cited roughly 250 compounds progressing from the initial pool.

3. Clinical trials

   • Phase I: Initial human studies, generally focused on safety and how the drug behaves in the body.
   • Phase II: Studies in a limited patient group to examine preliminary efficacy and safety.
   • Phase III: Larger, more varied groups; comparison with existing treatments and evaluation of the risk–benefit balance.
   • The lecturer said only a small number—about five on average from the preclinical pool—progress to human studies.

4. Regulatory review and registration

   • Companies or other applicants submit the required evidence to the relevant regulator. In Brazil, this is Anvisa; the lecture also mentioned the FDA in the United States.
   • Registration concerns whether the product has adequate evidence and is produced under appropriate conditions.

5. Phase IV and pharmacovigilance

   • Monitoring continues after a medicine reaches the market.
   • Real-world use can reveal uncommon or delayed adverse effects, quality problems, or information relevant to new indications.
   • Safety findings can lead to changes in a medicine’s use, recalls of particular batches, or withdrawal from the market. The lecture said Brazilian registration must be renewed periodically.

The lecturer characterized development as a long, costly process, citing an estimate of around 15 years and more than US$1 billion. The key message was that promising early findings are not enough: a treatment must demonstrate appropriate safety and efficacy through successive stages.

4. Scientific Literacy and Responsible Interpretation

A recurring theme was the need to distinguish preliminary findings from reliable evidence:

• A result in a laboratory cell culture does not establish that a treatment is safe or effective in people.
• Animal and in-vitro findings do not automatically translate to human treatment.
• Clinical studies need sound methods and controls so researchers can separate a treatment’s effect from other influences.
• Healthcare professionals and journalists have a responsibility to communicate evidence accurately, since unsupported claims can shape public decisions and create false hope.

The lecturer discussed ivermectin and hydroxychloroquine as examples of treatments promoted for COVID-19 despite evidence that did not establish their effectiveness for that purpose. The lecture also referred to fosfoethanolamine and ongoing research on polylaminin, stressing that promising results should not be presented as proof of safety and efficacy before the evidence is adequate.

5. Bioethics and Protection of Research Participants

The four principles highlighted for clinical research were:

• Autonomy
• Beneficence
• Non-maleficence
• Justice

The lecturer also emphasized good clinical practices and the responsibility to protect participants’ safety, welfare, and rights.

Historical examples illustrated why safeguards are necessary:

• Tuskegee syphilis study: The lecturer described Black men with syphilis being observed without being properly informed or given available treatment, and treatment being obstructed even after penicillin became available.
• Unproven cancer treatment: Fosfoethanolamine was described as having been distributed with claims of curing cancer before adequate evidence supported those claims.

The core ethical lesson was that researchers must not allow hopes for a positive result to bias the conduct or interpretation of a study.

6. Pharmacology’s History and Scope

The lecture sketched a broad history: early use of natural materials and herbal remedies, followed by the isolation of active compounds, the development of synthetic medicines, and modern drug research. It noted that historical use can be valuable, but age or tradition alone does not establish that a treatment works or is safe.

Pharmacology connects with many fields, including pharmacokinetics, pharmacodynamics, pharmaceutical chemistry, pharmacognosy, toxicology, clinical pharmacology, neuropharmacology, cardiovascular and gastrointestinal pharmacology, pharmacogenetics, pharmacogenomics, pharmacoepidemiology, and pharmacoeconomics.

7. Important Terminology

The lecturer distinguished several terms that are often used interchangeably in everyday speech:

• Drug / active ingredient: The chemical substance responsible for a medicine’s biological activity.
• Medicine: A prepared pharmaceutical product containing one or more active ingredients, made in a defined form and subject to scientific and regulatory requirements.
• Remedy: A broader term for something used to relieve discomfort or symptoms; it need not be a registered medicine.
• Medication: The lecturer used this to mean the act or process of administering a medicine.
• Drug material (“droga” in the lecture’s Portuguese terminology): The plant, animal, or mineral source from which an active substance may be obtained. The lecture cautioned against using this term as a synonym for every medicine.

The lecture also distinguished:

• Reference medicine: The original product associated with the active ingredient and its initial patent.
• Generic medicine: A product intended to be interchangeable with the reference product, supported by bioequivalence requirements.
• Similar medicine: A product with the same active ingredient but a different brand. The lecturer noted that interchangeability depends on applicable evidence and regulatory criteria.

8. Formulation, Dosage Form, and Administration Route

A medicine’s pharmaceutical formula describes its ingredients and their quantities. Its dosage form describes how it is presented—for example, as a tablet, capsule, solution, cream, or ointment. Formulation can affect when and where a medicine dissolves and how it is absorbed.

Routes discussed included oral, intravenous, intramuscular, subcutaneous, intradermal, inhaled, topical, ocular, ear, rectal, vaginal, and intranasal administration. Route selection depends on the treatment goal, the patient’s circumstances, and the properties of the formulation. The lecture contrasted the convenience of oral administration with the speed or direct availability that some non-oral routes can provide.

9. Pharmacology Concepts and Interpretation of Graphs

The lecturer explained several related but distinct concepts:

• Potency: How much of a drug is needed to produce an effect; a more potent drug generally produces a given effect at a lower dose.
• Efficacy: The maximum effect a drug can produce under controlled conditions.
• Effectiveness: How well the drug performs in ordinary, real-world use.
• Efficiency: A comparison that considers outcomes in relation to cost or ease of use.

Students were also shown how to read concentration–time curves by comparing a medicine’s plasma concentration with a minimum effective concentration and a maximum safe concentration. A suitable formulation should reach the effective range without exceeding the safe range.

The therapeutic index was presented as a way to compare effective and harmful or lethal doses: a wider separation generally indicates a greater safety margin. Barbiturates and benzodiazepines were used to illustrate differences in safety margin.

10. The Stages of a Medicine’s Action in the Body

The lecture described a sequence from formulation to patient outcome:

1. Pharmaceutical phase: The dosage form breaks apart and the active ingredient dissolves.
2. Pharmacokinetic phase: The body absorbs, distributes, metabolizes, and eliminates the drug. First-pass metabolism in the liver may affect how much reaches the circulation.
3. Pharmacodynamic phase: The drug interacts with biological targets and produces pharmacological effects.
4. Pharmacotherapeutic outcome: The clinical team evaluates whether the effect benefits the patient and whether treatment should be adjusted.

The lecturer emphasized that patient factors—including age, pregnancy, kidney or liver function, other conditions, and other medicines—can change the response. Selecting and monitoring treatment therefore requires attention to the individual, not just the drug.

Speakers and Sources Featured

Speakers

• Professor Jessica Bonato — Introduced the course, explained module logistics, and facilitated the session.
• Professor Barbara — The lecturer identified as a pharmacist with graduate training in pharmacology; her surname was not clear in the subtitles.
• Students participating through the chat — Asked questions and commented during the lesson.

Sources and Figures Mentioned

• Alexander Fleming — Penicillin discovery story.
• Aristotle — Quoted in a discussion of ethics and justice.
• Mário Sérgio Cortella — Quoted on acting with the resources available rather than waiting for ideal circumstances.
• James Lind — Mentioned in relation to scurvy, diet, and citrus fruits.
• Tuskegee syphilis study and a New York Times journalist — Referenced in the discussion of research ethics.
• Anvisa, the FDA, and the World Health Organization — Cited as regulatory or public-health bodies.
• Fiocruz — Mentioned as offering a course on good clinical practices.
• Professor Eliézer Barreiro — Described as a Brazilian figure in pharmaceutical chemistry and drug development.
• Mário Sérgio Cortella’s tennis-player anecdote — The athlete was not identified in the subtitles.
• Drugs and treatments discussed as examples: Penicillin, amoxicillin, clavulanate, ivermectin, hydroxychloroquine, fosfoethanolamine, polylaminin, Viagra, Dramamine, minoxidil, barbiturates, and benzodiazepines.

Note: The subtitles contain apparent transcription or lecture inaccuracies. In particular, they describe penicillin as a peptide; that claim is incorrect, and oral suitability depends on the specific penicillin and formulation.